KCA
YARW

KVP Capital Advisors’s Yarrow Bioscience YARW Stock Holding History

KVP Capital Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Hold
10,011
– – 0.24% 35
2026
Q1 		$299K Hold
10,011
– – 0.22% 32
2025
Q4 		$290K Buy
+10,011
New +$201K 0.28% 27

Other funds holding YARW

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

KVP Capital Advisors's YARW Position: Q2 2026 in Review

KVP Capital Advisors held its Yarrow Bioscience (YARW) position steady in Q2 2026 at 10,011 shares worth $326K. The position accounts for 0.24% of the portfolio, ranked #35.

KVP Capital Advisors first reported a position in YARW in Q4 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

  • KVP Capital Advisors held 10,011 shares of Yarrow Bioscience worth $326K as of Q2 2026.
  • KVP Capital Advisors left its Yarrow Bioscience share count unchanged in Q2 2026.
  • Yarrow Bioscience made up 0.24% of KVP Capital Advisors's portfolio in Q2 2026, its #35 holding.
  • KVP Capital Advisors first reported a position in Yarrow Bioscience in Q4 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.